Earnings summaries and quarterly performance for HeartSciences.
Research analysts covering HeartSciences.
Recent press releases and 8-K filings for HSCS.
HeartSciences’ MyoVista Insights Selected by Cibolo Rural Health Networks
HSCS
New Projects/Investments
Product Launch
- HeartSciences Inc. announced that Cibolo Rural Health Networks (Cibolo Health) has selected its MyoVista Insights™ platform as the endorsed ECG management solution for independent hospitals within its high-value networks.
- This collaboration will provide Cibolo Health’s network of 123 independent hospitals across six states with access to the cloud-native ECG management platform.
- The MyoVista Insights platform is designed to improve workflow efficiency, data accessibility, and clinical decision-making, and provides a scalable foundation for integrating regulatory-compliant AI-ECG algorithms.
Jan 29, 2026, 1:30 PM
HeartSciences Inc. Enters Promissory Note Agreement
HSCS
Debt Issuance
- HeartSciences Inc. (HSCS) entered into a Note Purchase Agreement with Streeterville Capital, LLC on January 13, 2026, for an unsecured promissory note with an original principal amount of $3,605,000.00.
- The company received gross proceeds of $3,000,000.00 from the note, after accounting for an original issue discount of $600,000.00 and $5,000.00 in transaction expenses.
- The note bears an interest rate of 12% per annum and matures 18 months after its issuance date.
- Streeterville Capital, LLC may require redemption of up to $405,000 per month starting six months after issuance, and the outstanding balance will automatically increase by 5% if not reduced by at least $1,250,000.00 by the 12-month anniversary.
Jan 16, 2026, 10:15 PM
HeartSciences Reports Fiscal Second Quarter 2026 Results and Business Updates
HSCS
Earnings
Product Launch
New Projects/Investments
- HeartSciences Inc. reported no meaningful revenue for its fiscal second quarter ended October 31, 2025.
- As of October 31, 2025, the company had approximately $2.0 million in cash and cash equivalents and $4.2 million in shareholders' equity.
- The company made significant progress with its MyoVista Insights™ healthcare IT platform, which is exempt from 510(k) clearance, and is engaged in commercial discussions with healthcare institutions.
- HeartSciences also submitted its MyoVista® wavECG™ device to the FDA for 510(k) premarket clearance.
Dec 15, 2025, 9:17 PM
HeartSciences Reports Fiscal Second Quarter 2026 Results and Business Update
HSCS
Earnings
Product Launch
New Projects/Investments
- HeartSciences reported no meaningful revenue for its fiscal second quarter ended October 31, 2025 (FQ2 2026).
- As of October 31, 2025, the company had approximately $2.0 million in cash and cash equivalents and $4.2 million in shareholders' equity.
- The company submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (FDA) for 510(k) premarket clearance.
- HeartSciences is making progress in the commercialization of its MyoVista Insights™ healthcare IT platform, which launched in May 2025 and is exempt from 510(k) clearance, and expects to announce key customer wins soon.
Dec 15, 2025, 9:15 PM
HeartSciences Submits MyoVista wavECG Device to FDA for 510(k) Clearance
HSCS
Product Launch
New Projects/Investments
- HeartSciences Inc. submitted its MyoVista® wavECG™ device to the U.S. Food and Drug Administration (FDA) for 510(k) premarket clearance.
- The company strategically separated the FDA submissions for the MyoVista wavECG device and its AI-ECG software algorithm to align with new clinical standards and accelerate device clearance.
- This submission is considered an important regulatory milestone for the company's commercialization strategy, with expectations for initial customer deployments of its MyoVista InsightsTM platform.
Dec 15, 2025, 1:30 PM
HeartSciences Inc. extends loan maturity, raises capital, and converts debt
HSCS
Debt Issuance
Convertible Preferred Issuance
New Projects/Investments
- HeartSciences Inc. and Front Range Ventures LLC entered into Amendment No. 7 to their Loan and Security Agreement and a No. 3 Amended and Restated Secured Promissory Note on September 26, 2025, extending the maturity date of the $500,000 loan to September 30, 2026, with an interest rate of 12% per annum, compounded annually.
- As of October 1, 2025, the company received $6.7 million in gross proceeds from its Regulation A Offering, resulting in the issuance of 1,912,383 Units.
- Also as of October 1, 2025, HeartSciences Inc. completed a debt exchange, converting $2,060,000 in principal and $45,000 of accrued interest from an unsecured promissory note into 597,578 shares of common stock.
- Following these transactions, there are 3,069,635 shares of common stock issued and outstanding as of October 1, 2025.
Oct 1, 2025, 9:23 PM
HeartSciences Reports Q1 2026 Financial Results and Business Updates
HSCS
Earnings
Product Launch
New Projects/Investments
- HeartSciences Inc. reported no meaningful revenue for the first quarter of fiscal 2026, which ended July 31, 2025.
- As of July 31, 2025, the company had approximately $2.8 million in cash and cash equivalents and $3.1 million in shareholders’ equity.
- The company successfully launched its MyoVista Insights™ software platform and received an FDA Breakthrough Device Designation for its aortic stenosis ECG algorithm.
- Subsequent to the quarter, HeartSciences strengthened its balance sheet by raising an additional $0.8 million through a Reg A+ offering and converting $0.7 million of debt into equity.
Sep 11, 2025, 8:28 PM
HeartSciences Reports FQ1 2026 Financial Results and Business Updates
HSCS
Earnings
Product Launch
New Projects/Investments
- HeartSciences reported no meaningful revenue for the first quarter of fiscal 2026, which ended July 31, 2025. As of that date, the company had approximately $2.8 million in cash and cash equivalents, and $3.1 million in shareholders’ equity.
- Subsequent to FQ1 2026, HeartSciences raised an additional $0.8 million through its Reg A+ offering and exchanged $0.7 million of debt into equity.
- The company successfully launched MyoVista Insights, a cloud-native software platform designed for AI-ECG algorithms, and received FDA Breakthrough Device Designation for its aortic stenosis ECG algorithm.
- CPT reimbursement codes are now in place for AI-ECG, covering algorithms provided by MyoVista Insights, which is expected to support AI-ECG adoption.
Sep 11, 2025, 8:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more